Last reviewed · How we verify
Cornerstone Health Care, PA — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Combigan Two Times Daily (BID) | Combigan Two Times Daily (BID) | marketed | Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker | Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors | Ophthalmology | |
| Natalizumab (Tysabri) | Natalizumab (Tysabri) | marketed | Monoclonal antibody; integrin antagonist | α4β1 integrin (VLA-4) | Immunology; Neurology; Gastroenterology |
Therapeutic area mix
- Immunology; Neurology; Gastroenterology · 1
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Cornerstone Health Care, PA:
- Cornerstone Health Care, PA pipeline updates — RSS
- Cornerstone Health Care, PA pipeline updates — Atom
- Cornerstone Health Care, PA pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Cornerstone Health Care, PA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cornerstone-health-care-pa. Accessed 2026-05-16.